CoChat

Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis

Open access
Abbasi, Ahmed, Peeke, Stephen, Shah, Nishi, Mustafa, Jennat, Khatun, Fariha, Lombardo, Amanda, Abreu, Michelly, Elkind, Richard, Fehn, Karen, de Castro, Alyssa, Wang, Yanhua, Derman, Olga, Nelson, Randin, Uehlinger, Joan, Gritsman, Kira, Sica, R. Alejandro, Kornblum, Noah, Mantzaris, Ioannis, Shastri, Aditi, Janakiram, Murali, Goldfinger, Mendel, Verma, Amit, Braunschweig, Ira, Bachier-Rodriguez, Lizamarie · 2020 · Journal of Hematology & Oncology
Cited by 203

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FDA approval in an inner-city tertiary center in the Bronx. Eight patients (80%) had received ≥ 3 lines of therapy, six patients had received prior radiation, and seven had recurrent disease after prior autologous hematopoietic stem cell transplant (AHCT). Our cohort included one patient with HIV, two patients with hepatitis B, and two patients with CNS involvement of lymphoma. Axi-cel treatment led to significant responses with 8/10 patients achieving a complete remission at 3 months, including both patients with prior CNS involvement. The treatment was generally well tolerated with 20% of patients experiencing grade ≥ 2 CRS. One patient each with HIV and hepatitis B responded without significant toxicities. In conclusion, Axi-cel led to significant efficacy with manageable toxicity in DLBCL in a real-world setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-019-0838-y

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 203

Metadata

Authors
Abbasi, A., Peeke, S., Shah, N., Mustafa, J., Khatun, F., Lombardo, A., Abreu, M., Elkind, R., Fehn, K., de Castro, A., Wang, Y., Derman, O., Nelson, R., Uehlinger, J., Gritsman, K., Sica, R. A., Kornblum, N., Mantzaris, I., Shastri, A., Janakiram, M., Goldfinger, M., Verma, A., Braunschweig, I., & Bachier-Rodriguez, L.
Venue
Journal of Hematology & Oncology
Published
2020-01-03
Volume
13
Issue
1
Pages
1-1
ISSN
1756-8722 (ISSN-L)
OpenAlex
W3000719174
Cited by
203
References
4
FWCI
9.86
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. https://app.cochat.ai/papers/10.1186/s13045-019-0838-y
The paper
Abbasi, A., Peeke, S., Shah, N., Mustafa, J., Khatun, F., Lombardo, A., Abreu, M., Elkind, R., Fehn, K., de Castro, A., Wang, Y., Derman, O., Nelson, R., Uehlinger, J., Gritsman, K., Sica, R. A., Kornblum, N., Mantzaris, I., Shastri, A., . . . Bachier-Rodriguez, L. (2020). Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-019-0838-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.